Clinical Trial Update: Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial in Korean patients investigates whether UGT1A1 genetic polymorphisms influence irinotecan toxicity in colorectal and gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer

Drugs mentioned

• Camptosar (irinotecan)

Snippet

Sponsor: Asan Medical Center | Conditions: Stage IV Colorectal Cancer, Gastric Cancer | Phase 4 | Status: UNKNOWN